Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. - Wikidata - awgldk - TriplyDB

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

http://www.wikidata.org/entity/Q35485799

about

Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?Biomarkers in Multiple Sclerosis: An Up-to-Date Overview Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis A panel of neuron-enriched proteins as markers for traumatic brain injury in humans.Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation.Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Toward biomarkers in multiple sclerosis: new advances.The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology.Noninvasive assessments of optic nerve neurodegeneration in transgenic mice with isolated optic neuritis.Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON)Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.Protecting axons in multiple sclerosis.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.Review on intermediate filaments of the nervous system and their pathological alterations.Molecular biomarkers of neurodegeneration.Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis.Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis.Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis.The relationship between subjective reports of fatigue and executive control in multiple sclerosis N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.Cerebrospinal fluid ATP metabolites in multiple sclerosis.Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks.Amniotic fluid brain-specific proteins are biomarkers for spinal cord injury in experimental myelomeningocele.Degeneration of corpus callosum and recovery of motor function after stroke: a multimodal magnetic resonance imaging study.Science is 1% inspiration and 99% biomarkers.The Relationship Between Neurocognitive Behavior of Executive Functions and the EFPT in Individuals with Multiple Sclerosis.

P2860

Q21558407-13C2DDE0-D1D4-48F2-96AE-6253260B52D2 Q26799233-DDA50EDC-C98D-43E6-B588-F28E7FE15529 Q27496017-457F47FA-5009-47DB-8669-0FFEF4D5109C Q30712257-1ED8F007-26F6-49AC-97C2-2DCEEAAFEB8B Q33414966-60DD4B9D-EC39-4402-93BC-B367EE349D3F Q33657708-B1905666-EDCA-42F1-8851-576916C185A4 Q34078026-9CBEECBA-6A14-4000-A3FA-D6660F040B43 Q34924891-B02739FA-C543-4793-A36D-507F89126F06 Q35078327-48220720-A2F2-487A-A21E-C067B3DABABA Q35878624-16AF328C-49FA-405A-A43A-97F979B0CCCD Q36327377-F5DB4377-4FC6-42D8-A5B0-7B6369ACB37B Q36492380-30C7C355-861B-4316-88C0-45BAAB1CB789 Q36500261-CDC65050-3C6F-4473-A496-971198883B8A Q36973566-D0CACD73-5FA3-446B-83F4-8A4EFDCBBFBE Q36979239-A0C3903E-88EA-4367-AFDA-A59A1F529448 Q37021025-3144C248-E6B8-470D-BC4B-8F27B35DB963 Q37206262-C2F9F533-9946-4739-873C-0BA3EA6E2C03 Q37218580-0BF36CC8-3F25-467F-847C-24382EDF0C24 Q38088747-27D77744-C6C8-4338-B75E-2D18B1C45463 Q38092972-0A11B52F-9C51-4B76-96DB-1986FF47D771 Q38113164-EDD0D0EB-53E4-4EA6-989E-F8E7C7C566B6 Q38154930-02397CB2-EC9D-4D71-8209-C3EA7D5D8149 Q38713740-5020BF41-8E19-4A4B-BB5B-82B1AA622F3B Q38737766-96A7387D-542D-4454-9FB0-211C9CF85099 Q38782456-1D169B95-4E8E-4AB0-B59D-2E7B2E1421BB Q39027028-8D3B34B3-BE70-4969-8058-57F881EB611B Q39748242-0FA84E1E-1001-4505-9C20-DDBA0A714088 Q40997871-54ED10AB-378F-4583-8F37-0EF23D6EDFEF Q41909448-982E2756-564E-4C49-BF4A-54955B81685C Q42683530-E3547D0D-F164-41AE-94DA-F2379F6A0926 Q43145621-B5DEB027-892A-4110-B95E-740056D08C36 Q44028578-920C7059-6289-46D8-BB63-F260AAA79ACD Q46766236-DB293DDE-713D-437E-80CA-A8221C11A842 Q47579410-DA4347E3-A086-4C54-90ED-56330BB3CDEB Q48482480-58EB4752-4D5B-486E-9A3C-48B5F041E27E Q48681179-53FB2F39-DFF5-4020-B7A6-BCD6BE99153B Q48763817-0C48AE81-9934-495A-AB52-AF6C795BCF08 Q48824529-698D2512-AAC7-4001-BB7E-345329C8E41D Q50984144-5771AA14-DE2C-496A-B5AC-3898DD51E67C Q51522883-C4CF69E4-83A6-4807-A2AD-30A5942E9D40

P2860

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

http://www.wikidata.org/entity/Q35485799

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Axonal damage accumulates in t ...... s: three year follow up study.

@ast

Axonal damage accumulates in t ...... s: three year follow up study.

@en

type

label

Axonal damage accumulates in t ...... s: three year follow up study.

@ast

Axonal damage accumulates in t ...... s: three year follow up study.

@en

prefLabel

Axonal damage accumulates in t ...... s: three year follow up study.

@ast

Axonal damage accumulates in t ...... s: three year follow up study.

@en

P1433

Q35485799-8EDC06CE-D7D5-43B3-9286-BC71CE8607F0

P1476

Q35485799-5102E1BC-2A61-490E-B580-63341C398DE3

P2093

Q35485799-0A7BE4C2-ECDD-4A25-8132-47FD6F60BBD4

Q35485799-111D325E-AD41-477D-B041-BABDDC3D7B5B

Q35485799-91F29EA6-B304-4D13-AFE3-C1F146BA431D

Q35485799-B7C5A92F-FB33-4472-B2CA-660AEDF74E90

Q35485799-C141D3D4-3365-40D5-844C-A6D953512D36

Q35485799-DA69E3EE-C954-44DF-ACE0-7D50E5260444

Q35485799-E563664B-C51B-43BA-9A3B-6F5491C68EDB

P2860

Q35485799-0592F677-F20A-41E0-AA7E-9A685F9E0FE7

Q35485799-0D5DF5B4-911E-40D0-A2AA-893FA4DCF289

Q35485799-0DE78049-B6CD-4B48-92AA-AA642015B4D0

Q35485799-13449E6F-E7C5-4F91-A53F-BC407A1A25D8

Q35485799-173FB89B-966A-4516-A90B-066CA48EB980

Q35485799-1FEAD7DF-DE25-4C5A-B8B0-549DE9E6B688

Q35485799-25F1F9C0-C261-46AF-AAF3-FEF7A4E4A366

Q35485799-35FCB30B-9087-4C76-AC0D-12D73EAFE6C6

Q35485799-37FE4C0B-DC0B-4065-A6F5-9826044C20B4

Q35485799-3E213A18-FD45-464D-9883-EB38C53A9178

P304

Q35485799-43F5B2E4-5337-4F45-A0BE-C197B14A9D4E

P31

Q35485799-420CEBCC-3063-4F5F-A035-D78F2F86160A

P356

Q35485799-C0C0A757-25CD-458E-B2EC-0CC61866E0F1

P407

Q35485799-DA23F3B2-1369-494A-877D-23B4E4D40106

P433

Q35485799-DB072326-95CF-4F8C-951B-93512DA87992

P478

Q35485799-28E0440B-8460-4201-96B9-7D671D70358D

P50

Q35485799-2EFCD38B-5A9C-40F1-A47F-90A6AC6A4A63

Q35485799-BC7E97BB-84B2-44F1-84AD-52F832DFB6B1

P577

Q35485799-304CA688-DD03-4703-9E03-95B58BCD3687

P5875

Q35485799-E48D15C9-484E-48AA-85D2-52584D443012

P698

Q35485799-EC170A71-A6CF-4681-8639-CF965F991719

P921

Q35485799-F0D4757A-5F14-41F5-9617-CD77C5C73FE7

P932

Q35485799-82A91C8B-D484-4CDC-95D7-24979F2CD28D

P356

JNNP.2004.043315

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Axonal damage accumulates in t ...... is: three year follow up study

@en

P2093

B M J Uitdehaag

http://www.w3.org/2001/XMLSchema#string

C H Polman

http://www.w3.org/2001/XMLSchema#string

D Grant

http://www.w3.org/2001/XMLSchema#string

E J Thompson

http://www.w3.org/2001/XMLSchema#string

G Giovannoni

http://www.w3.org/2001/XMLSchema#string

G Keir

http://www.w3.org/2001/XMLSchema#string

M J Eikelenboom

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

Axonal transection in the lesions of multiple sclerosis

The clinico-radiological paradox in multiple sclerosis revisited.

Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration.

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.

Neurofilament protein synthesis and phosphorylation.

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.

P304

206-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2004.043315

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8077451

http://www.w3.org/2001/XMLSchema#string

P698

15654034

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

1739484

http://www.w3.org/2001/XMLSchema#string